Sweden's ChemoTech Q4 sales rise on Animal Care unit strength

Reuters

02/17

Sweden's ChemoTech Q4 sales rise on Animal Care unit strength

Overview

Swedish medical tech firm's Q4 net sales rose yr/yr, driven by Animal Care segment
Q4 operating cash flow improved significantly compared to last year
Company reports strong Animal Care sales and first U.S. order from equine clinic

Outlook

ChemoTech plans initial technical tests for next-gen vetIQure platform in 2026
Company sees North America as key market opportunity for growth
ChemoTech aims to strengthen presence in Europe as market conditions evolve

Result Drivers

ANIMAL CARE SALES - Strong Q4 sales in Animal Care segment exceeded expectations despite anticipated seasonal slowdown
U.S. MARKET ENTRY - First U.S. order from leading equine clinic in Kentucky marks significant market entry
TREATMENT KIT SALES - Cumulative number of treatment kits sold more than doubled from 2024, driven by higher utilization and confidence

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q4 Sales		SEK 2.65 mln
Q4 EPS		-SEK 0.10
Q4 Operating Cash Flow		-SEK 338,000

Analyst Coverage

Wall Street's median 12-month price target for Scandinavian ChemoTech AB is SEK6.30, about 67.6% above its February 16 closing price of SEK3.76

Press Release: ID:nWkr1q9DYr

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

應版權方要求，你需要登入查看該內容

登入 / 註冊

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2612443036"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2612443036\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2612443036?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-02-17 15:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2612443036","market":"fut","top_or_hot":-1,"title":"Sweden's ChemoTech Q4 sales rise on Animal Care unit strength","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Sweden's ChemoTech Q4 sales rise on Animal Care unit strength</title></head><body><p><span>Overview</span></p><ul><li><p>Swedish medical tech firm's Q4 net sales rose yr/yr, driven by Animal Care segment</p></li><li><p>Q4 operating cash flow improved significantly compared to last year</p></li><li><p>Company reports strong Animal Care sales and first U.S. order from equine clinic</p></li></ul><p><span>Outlook</span></p><ul><li><p>ChemoTech plans initial technical tests for next-gen vetIQure platform in 2026</p></li><li><p>Company sees North America as key market opportunity for growth</p></li><li><p>ChemoTech aims to strengthen presence in Europe as market conditions evolve</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ANIMAL CARE SALES - Strong Q4 sales in Animal Care segment exceeded expectations despite anticipated seasonal slowdown</p></li><li><p>U.S. MARKET ENTRY - First U.S. order from leading equine clinic in Kentucky marks significant market entry</p></li><li><p>TREATMENT KIT SALES - Cumulative number of treatment kits sold more than doubled from 2024, driven by higher utilization and confidence</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Sales</p></td><td></td><td><p>SEK 2.65 mln</p></td><td></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-SEK 0.10</p></td><td></td></tr><tr><td><p>Q4 Operating Cash Flow</p></td><td></td><td><p>-SEK 338,000</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>Wall Street's median 12-month price target for Scandinavian ChemoTech AB is SEK6.30, about 67.6% above its February 16 closing price of SEK3.76</p></li></ul><p>Press Release: <span>ID:nWkr1q9DYr</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sweden's ChemoTech Q4 sales rise on Animal Care unit strength</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSweden's ChemoTech Q4 sales rise on Animal Care unit strength\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2026-02-17 15:39</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>Sweden's ChemoTech Q4 sales rise on Animal Care unit strength</title></head><body><p><span>Overview</span></p><ul><li><p>Swedish medical tech firm's Q4 net sales rose yr/yr, driven by Animal Care segment</p></li><li><p>Q4 operating cash flow improved significantly compared to last year</p></li><li><p>Company reports strong Animal Care sales and first U.S. order from equine clinic</p></li></ul><p><span>Outlook</span></p><ul><li><p>ChemoTech plans initial technical tests for next-gen vetIQure platform in 2026</p></li><li><p>Company sees North America as key market opportunity for growth</p></li><li><p>ChemoTech aims to strengthen presence in Europe as market conditions evolve</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>ANIMAL CARE SALES - Strong Q4 sales in Animal Care segment exceeded expectations despite anticipated seasonal slowdown</p></li><li><p>U.S. MARKET ENTRY - First U.S. order from leading equine clinic in Kentucky marks significant market entry</p></li><li><p>TREATMENT KIT SALES - Cumulative number of treatment kits sold more than doubled from 2024, driven by higher utilization and confidence</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q4 Sales</p></td><td></td><td><p>SEK 2.65 mln</p></td><td></td></tr><tr><td><p>Q4 EPS</p></td><td></td><td><p>-SEK 0.10</p></td><td></td></tr><tr><td><p>Q4 Operating Cash Flow</p></td><td></td><td><p>-SEK 338,000</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>Wall Street's median 12-month price target for Scandinavian ChemoTech AB is SEK6.30, about 67.6% above its February 16 closing price of SEK3.76</p></li></ul><p>Press Release: <span>ID:nWkr1q9DYr</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4533","symbol_name":"AQR資本管理(全球第二大對沖基金)","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260217:nL1N3ZD06F:1","article_id":"2612443036","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2612443036","pubTimestamp":1771313964,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Sweden's ChemoTech Q4 sales rise on Animal Care unit strengthOverviewSwedish medical tech firm's Q4 net sales rose yr/yr, driven by Animal Care segmentQ4 operating cash flow improved significantly com","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4533":"AQR资本管理(全球第二大对冲基金)","LU0154245756.USD":"BNP PARIBAS US MID CAP \"C\" (USD) ACC","BK4149":"建筑机械与重型卡车","BK4588":"碎股","BK4567":"ESG概念","BK4585":"ETF&股票定投概念","CMI":"康明斯","LU0154245673.USD":"BNP PARIBAS US MID CAP \"C\" (USD) INC","LU0203345920.USD":"SCHRODER ISF QEP GLB ACT. VL \"A\" (USD) ACC","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV"},"translate_title":"瑞典ChemoTech第四季度销售额因动物护理部门实力而增长","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CMI":0.9},"content_text":"Sweden's ChemoTech Q4 sales rise on Animal Care unit strengthOverviewSwedish medical tech firm's Q4 net sales rose yr/yr, driven by Animal Care segmentQ4 operating cash flow improved significantly compared to last yearCompany reports strong Animal Care sales and first U.S. order from equine clinicOutlookChemoTech plans initial technical tests for next-gen vetIQure platform in 2026Company sees North America as key market opportunity for growthChemoTech aims to strengthen presence in Europe as market conditions evolveResult DriversANIMAL CARE SALES - Strong Q4 sales in Animal Care segment exceeded expectations despite anticipated seasonal slowdownU.S. MARKET ENTRY - First U.S. order from leading equine clinic in Kentucky marks significant market entryTREATMENT KIT SALES - Cumulative number of treatment kits sold more than doubled from 2024, driven by higher utilization and confidenceKey DetailsMetricBeat/MissActualConsensus EstimateQ4 SalesSEK 2.65 mlnQ4 EPS-SEK 0.10Q4 Operating Cash Flow-SEK 338,000Analyst CoverageWall Street's median 12-month price target for Scandinavian ChemoTech AB is SEK6.30, about 67.6% above its February 16 closing price of SEK3.76Press Release: ID:nWkr1q9DYrFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}